Form 4: Mineralys Therapeutics CFO Adam Levy Sells Shares Under 10b5-1 Trading Plan

Adam Levy, CFO and Secretary of Mineralys Therapeutics, sold 10,757 shares of common stock at a weighted-average price of $13.5729 on October 11, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On October 11, 2024, Adam Levy, the CFO and Secretary of Mineralys Therapeutics, sold 10,757 shares of the company's common stock.
• The sale was executed at a weighted-average price of $13.5729 per share.
• The transactions occurred at prices ranging from $13.24 to $13.76.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 14, 2023.
• Following the transaction, Levy directly owns 236,854 shares of Mineralys Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was executed under a pre-planned trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. Investors often monitor these sales for signals about management's confidence in the company's future prospects.

Stakeholder Impact

• The sale of shares by a company officer could be perceived negatively by some shareholders, potentially leading to slight downward pressure on the stock price in the short term.

Key Dates